Efficacy of angiotensin II type 1 receptor blockade on reperfusion-induced arrhythmias and mortality early after myocardial infarction is increased in transgenic rats with cardiac angiotensin II type 1 overexpression

Journal of Cardiovascular Pharmacology

Volumn 39, Issue 4, 2002, Pages 610-619

  De Boer, Rudolf A ^a   Van Geel, Peter P ^a   Pinto, Yigal M ^a   Suurmeijer, Albert J H ^a   Crijns, Harry J G M ^a   Van Gilst, Wiek H ^a   Van Veldhuisen, Dirk J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Arrhythmias; Infarction; Ischemia; Renin angiotensin system; Reperfusion

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; LOSARTAN;

ADRENERGIC RECEPTOR BLOCKING; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE OVEREXPRESSION; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE REPERFUSION; MALE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REPERFUSION INJURY; SURVIVAL; TRANSGENIC ANIMAL;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; DISEASE MODELS, ANIMAL; HUMANS; LOSARTAN; MALE; MYOCARDIAL INFARCTION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ANGIOTENSIN; REPERFUSION INJURY; VENTRICULAR FUNCTION, LEFT;

EID: 0036199892     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200204000-00017     Document Type: Article

References (56)

1. Neuroendocrine activation after acute myocardial infarction
2. Activation of angiotensin-converting enzyme expression in infarct zone following myocardial infarction
3. Effects of angiotensin II and captopril on inducible sustained ventricular tachycardia two weeks after myocardial infarction in the pig
4. Effects of early angiotensin-converting enzyme inhibition in a pig model of myocardial ischemia and reperfusion
5. ACE-inhibition induces NO-formation in cultured bovine endothelial cells and protects isolated ischemic rat hearts
6. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
7. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions
8. Amelioration by quinapril of myocardial infarction induced by coronary occlusion/reperfusion in a rabbit model of atherosclerosis: Possible mechanisms
9. Experimental cardiovascular benefits of angiotensin-converting enzyme inhibitors: Beyond blood pressure reduction
10. Increase in angiotensin II type 1 receptor expression immediately after ischemia-reperfusion in isolated rat hearts
11. Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction
12. Up-regulated expression of angiotensin II type 1 receptor gene in human pathologic hearts
13. Angiotensin II receptor binding following myocardial infarction in the rat
14. Losartan attenuates myocardial ischemia-induced ventricular arrhythmias and reperfusion injury in spontaneously hypertensive rats
15. Effects of the insurmountable angiotensin AT1 receptor antagonist candesartan and the surmountable antagonist losartan on ischemia/reperfusion injury in rat hearts
16. Angiotensin II type 1a receptor is involved in the occurrence of reperfusion arrhythmias
17. Opposite effects of angiotensin AT1 and AT2 receptor antagonists on recovery of mechanical function after ischemia-reperfusion in isolated working rat hearts
18. Paracrine systems in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats
19. Overexpression of the human angiotensin II type 1 receptor in the rat heart augments load-induced cardiac hypertrophy
20. Cardiac angiotensin II receptors: Studies on functional coupling in Sprague-Dawley rats and TGR(alphaMHC-hAT1) transgenic rats
21. Cardiac-specific expression of the human AT1 receptor in transgenic rats
22. The ligand binding site of the angiotensin AT1 receptor
23. Differential influences of angiotensin converting-enzyme inhibitors on the coronary circulation
24. Purine and oxypurine production in mitochondria of ischemic and reperfused myocardium
25. Selective and time related activation of the cardiac renin-angiotensin system after experimental heart failure: Relation to ventricular function and morphology
26. Effects of reperfusion on arrhythmias and death after coronary artery occlusion in the rat: Increased electrical stability independent of myocardial salvage
27. Arrhythmias and death after coronary artery occlusion in the rat: Continuous telemetric ECG monitoring in conscious, untethered rats
28. Renal function, neurohormonal activation, and survival in patients with chronic heart failure
29. Reduction of reperfusion arrhythmias in the ischemic isolated rat heart by angiotensin converting enzyme inhibitors: A comparison of captopril, enalapril, and HOE 498
30. Increased kallikrein expression protects against cardiac ischemia
31. Cardiac refractoriness in rats is reduced by angiotensin II
32. Regression of left ventricular hypertrophy prevents ischemia-induced lethal arrhythmias: Beneficial effect of angiotensin II blockade
33. Critical role of AT1 receptor expression after ischemia/reperfusion in isolated rat hearts: Beneficial effect of antisense oligodeoxynucleotides directed at AT1 receptor mRNA
34. Effects of an angiotensin II antagonist on ischemic and nonischemic isolated rat hearts
35. Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat
36. The effect of AT1 receptor antagonist on chronic cardiac response to coronary artery ligation in rats
37. Comparative effects of pretreatment with captopril and losartan on cardiovascular protection in a rat model of ischemia-reperfusion
38. Effects of the angiotensin AT1 receptor blocker candesartan on myocardial ischemic/reperfusion injury
39. Reduction of myocardial infarct size by ramiprilat is independent of angiotensin II synthesis inhibition
40. Is the A1166C polymorphism of the angiotensin II type 1 receptor involved in cardiovascular disease?
41. Effect of cardiac overexpression of the AT1-receptor on myocardial function and scar size in experimental myocardial infarction
42. Renin-angiotensin system components in the interstitial fluid of the isolated perfused rat heart: Local production of angiotensin I
43. Regulation of angiotensin II type I (AT1) receptor function
44. Molecular mechanisms of angiotensin II receptor internalization
45. Regional changes in angiotensin II receptor density after experimental myocardial infarction
46. Survival after myocardial infarction in rats: Captopril versus losartan
47. Formation and disposition of EXP3174, a pharmacologically active metabolite of the novel angiotensin II receptor antagonist Du753
48. Effects of an angiotensin II antagonist on ischemic and nonischemic isolated rat hearts
49. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)
50. Experimental evidence to support ELITE
51. Effects of losartan and captopril on QT dispersion in elderly patients with heart failure
52. Irbesartan reduces QT dispersion in hypertensive individuals
53. Losartan exerts antiarrhythmic activity independent of angiotensin II receptor blockade in simulated ventricular ischemia and reperfusion
54. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial (the Losartan Heart Failure Survival Study ELITE II)
55. Candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM): Rationale and design
56. Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: The OPTIMAAL trial design. Optimal therapy in myocardial infarction with the angiotenin IT antagonist losartan